Humanwell Healthcare (600079.SH): HWH217 tablets approved for clinical trials in (WHO Group 1) pulmonary arterial hypertension.
Renfu Medicine (600079.SH) announcement, the company's wholly-owned subsidiary Hubei Bio-Pharmaceutical Industry Technology Research Institute Co.,Ltd.
Humanwell Healthcare (600079.SH) announced that its wholly-owned subsidiary Hubei Biomedical Industry Technology Research Institute Co., Ltd. recently received the "Clinical Trial Approval Notice" for HWH217 tablets issued by the National Medical Products Administration, permitting the company to conduct clinical trials for the treatment of arterial pulmonary hypertension in the WHO Group 1.
Related Articles
"The 'China choice' of global SiC core customers: Why TIANYU SEMI (02658)?"
Guosen: RWA welcomes the era of strict supervision.
Wondershare Technology Group (300624.SZ) has upgraded its Wondershare Filmora desktop version: free video editing, better AI results!
"The 'China choice' of global SiC core customers: Why TIANYU SEMI (02658)?"
Guosen: RWA welcomes the era of strict supervision.
Wondershare Technology Group (300624.SZ) has upgraded its Wondershare Filmora desktop version: free video editing, better AI results!
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
